ALNYLAM PHARMACEUTICALS, INC. : BMO CUTS TARGET PRICE TO $290 FROM $318

Reuters2026/10/30 10:53

By:Reuters

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 10:02 AM

Reuters•2026/11/02 15:02

THE PNC FINANCIAL SERVICES GROUP, INC. : UBS CUTS TARGET PRICE TO $278 FROM $286

Reuters•2026/11/02 14:31

CARTER'S, INC. <CRI.N>: UBS CUTS TARGET PRICE TO $33 FROM $38

Reuters•2026/11/02 14:31

CHEVRON CORPORATION <CVX.N>: UBS RAISES TARGET PRICE TO $265 FROM $235

Reuters•2026/11/02 14:31